Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Current Assets

Biogen Inc., adjusted current assets

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Current assets 7,856,500 6,887,100 8,381,800 7,640,900 7,873,300
Adjustments
Add: Reserves for allowances 38,000 41,600 40,500 34,700 46,000
After Adjustment
Adjusted current assets 7,894,500 6,928,700 8,422,300 7,675,600 7,919,300

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The analysis of current assets between 2017 and 2021 reveals a fluctuating trend characterized by periodic volatility, specifically a peak in 2019 and a significant trough in 2020. After a slight contraction in 2018, assets expanded to a five-year high in 2019 before experiencing a sharp decline in 2020, followed by a substantial recovery in 2021.

Asset Volatility and Recovery
Current assets shifted from 7.87 billion US dollars in 2017 to a low of 6.89 billion US dollars in 2020. The most significant movement occurred between 2019 and 2020, where assets decreased by approximately 1.5 billion US dollars. However, by December 31, 2021, current assets recovered to 7.86 billion US dollars, effectively returning to the levels observed at the start of the analyzed period.
Correlation Between Current and Adjusted Assets
Adjusted current assets mirror the trajectory of standard current assets with high precision. Every increase or decrease in the primary current asset figure is reflected identically in the adjusted figures, indicating that the adjustments applied are independent of the primary drivers of asset fluctuation.
Stability of Adjustments
The variance between current assets and adjusted current assets remains consistently narrow and stable. The difference ranges from a minimum of 34.7 million US dollars in 2018 to a maximum of 46 million US dollars in 2017. This suggests that the adjustment is based on a relatively constant value or a stable accounting treatment that does not scale proportionally with the total volume of current assets.

AI Ask an analyst for more


Adjustments to Total Assets

Biogen Inc., adjusted total assets

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Total assets 23,877,300 24,618,900 27,234,300 25,288,900 23,652,600
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1 — — — 508,135 508,429
Add: Reserves for allowances 38,000 41,600 40,500 34,700 46,000
Less: Deferred tax asset2 1,415,100 1,369,500 3,232,100 2,153,900 595,900
After Adjustment
Adjusted total assets 22,500,200 23,291,000 24,042,700 23,677,835 23,611,129

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Deferred tax asset. See details »


The financial trajectory of the asset base between 2017 and 2021 is characterized by an expansion phase that peaked in 2019, followed by a period of contraction through 2021.

Total Asset Trend
Total assets exhibited a steady increase from 23.65 billion USD in 2017 to a peak of 27.23 billion USD in 2019. This growth was followed by a notable reduction to 24.62 billion USD in 2020 and a further decline to 23.88 billion USD by the end of 2021, returning the asset base to levels near those reported in 2017.
Adjusted Total Asset Trend
Adjusted total assets followed a similar overall pattern but exhibited lower volatility. Values rose from 23.61 billion USD in 2017 to a peak of 24.04 billion USD in 2019. A subsequent downward trend is observed, with values falling to 23.29 billion USD in 2020 and 22.50 billion USD in 2021.
Variance Analysis
A significant divergence between total assets and adjusted total assets occurred between 2017 and 2019. While the variance was marginal in 2017, it expanded substantially to peak at approximately 3.19 billion USD in 2019. This indicates that a considerable portion of the reported asset growth during this period consisted of items deemed necessary for adjustment. Post-2019, this gap narrowed and stabilized, with the difference remaining between 1.33 billion USD and 1.38 billion USD during the 2020 and 2021 fiscal years.

AI Ask an analyst for more


Adjustments to Current Liabilities

Biogen Inc., adjusted current liabilities

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Current liabilities 4,298,200 3,742,200 4,863,800 3,295,200 3,368,200
Adjustments
Less: Current restructuring reserve — — — — 500
After Adjustment
Adjusted current liabilities 4,298,200 3,742,200 4,863,800 3,295,200 3,367,700

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The analysis of current liabilities reveals a period of volatility characterized by a significant peak in 2019 and subsequent fluctuations through 2021. While obligations remained relatively stable during the 2017-2018 period, the following years exhibited more pronounced changes in short-term financial obligations.

Liability Trend Analysis
Current liabilities experienced a modest decrease from 3,368,200 thousand US$ in 2017 to 3,295,200 thousand US$ in 2018. This was followed by a substantial increase to 4,863,800 thousand US$ in 2019, representing the highest liability level in the observed period. A contraction occurred in 2020, with liabilities falling to 3,742,200 thousand US$, before rising again to 4,298,200 thousand US$ by the end of 2021.
Adjustment Variance Assessment
A comparison between reported current liabilities and adjusted current liabilities indicates that adjustments were minimal over the five-year span. The only variance is observed in 2017, where adjusted liabilities were 500 thousand US$ lower than reported liabilities. For the fiscal years 2018, 2019, 2020, and 2021, the adjusted values are identical to the reported current liabilities, indicating that no further adjustments were deemed necessary for those periods.

AI Ask an analyst for more


Adjustments to Total Liabilities

Biogen Inc., adjusted total liabilities

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Total liabilities 12,917,600 13,932,800 13,895,200 12,257,300 11,054,500
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — 508,135 508,429
Less: Deferred tax liability2 694,500 1,032,800 2,810,800 1,636,200 122,600
Less: Restructuring reserve — — — — 500
After Adjustment
Adjusted total liabilities 12,223,100 12,900,000 11,084,400 11,129,235 11,439,829

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Deferred tax liability. See details »


The liability profile demonstrates a period of expansion followed by a recent contraction. Total liabilities grew steadily from 2017 to 2020, peaking at approximately 13.93 billion US dollars, before declining to approximately 12.92 billion US dollars by the end of 2021.

Total Liabilities Progression
An upward trajectory was maintained between 2017 and 2020, representing an increase of approximately 26% over three years. The peak observed in 2020 was followed by a reduction of approximately 7.3% in 2021, indicating a recent decrease in the company's total obligations.
Adjusted Total Liabilities Performance
Adjusted liabilities exhibit a contrasting pattern to the raw totals between 2017 and 2019, where values decreased despite the rise in total liabilities. A sharp increase occurred in 2020, reaching 12.90 billion US dollars, followed by a decline to 12.22 billion US dollars in 2021.
Analysis of Liability Adjustments
A significant divergence between total and adjusted liabilities is observed starting in 2018. In 2019, the variance reached its maximum, with adjusted liabilities being approximately 2.81 billion US dollars lower than reported total liabilities. This indicates that substantial non-core or specific accounting adjustments were applied to the liability base during the mid-period of the analysis.
Comparative Variance Trends
While adjusted liabilities were higher than total liabilities in 2017, the trend reversed for all subsequent years. The narrowing of the gap in 2021 suggests a convergence between reported liabilities and adjusted figures, although a difference of approximately 694 million US dollars remains.

AI Ask an analyst for more


Adjustments to Stockholders’ Equity

Biogen Inc., adjusted total Biogen Inc. shareholders’ equity

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Total Biogen Inc. shareholders’ equity 10,896,200 10,700,300 13,343,200 13,039,600 12,612,800
Adjustments
Less: Deferred tax assets (liabilities), net1 720,600 336,600 421,300 517,700 473,200
Add: Reserves for allowances 38,000 41,600 40,500 34,700 46,000
Add: Restructuring reserve — — — — 500
Add: Noncontrolling interests 63,500 (14,200) (4,100) (8,000) (14,700)
After Adjustment
Adjusted total equity 10,277,100 10,391,100 12,958,300 12,548,600 12,171,400

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Deferred tax assets (liabilities), net. See details »


An analysis of the equity position reveals a trajectory of modest growth between 2017 and 2019, followed by a substantial contraction in 2020 and relative stabilization in 2021.

Total Shareholders' Equity Trends
Total shareholders' equity exhibited a steady upward trend from 2017 to 2019, rising from US$ 12,612,800 thousand to a peak of US$ 13,343,200 thousand. This growth was followed by a sharp decline in 2020, where equity dropped to US$ 10,700,300 thousand, representing a decrease of approximately 19.8% from the previous year. A slight recovery occurred in 2021, with the balance increasing to US$ 10,896,200 thousand.
Adjusted Total Equity Performance
Adjusted total equity closely tracked the movement of total equity during the initial growth phase, increasing from US$ 12,171,400 thousand in 2017 to US$ 12,958,300 thousand in 2019. A significant contraction was observed in 2020, with the value falling to US$ 10,391,100 thousand. Unlike the total equity figure, the adjusted equity continued to decline slightly in 2021, reaching US$ 10,277,100 thousand.
Analysis of Equity Variance
The difference between total shareholders' equity and adjusted total equity remained relatively consistent between 2017 and 2020. However, a notable divergence emerged in 2021, where the variance expanded to US$ 619,100 thousand. This represents the largest gap between the total and adjusted figures over the five-year period, suggesting a significant change in the adjustments applied to the equity balance in the final year of the analysis.

AI Ask an analyst for more


Adjustments to Capitalization Table

Biogen Inc., adjusted capitalization table

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Current portion of notes payable 999,100 — 1,495,800 — 3,200
Notes payable, excluding current portion 6,274,000 7,426,200 4,459,000 5,936,500 5,935,000
Total reported debt 7,273,100 7,426,200 5,954,800 5,936,500 5,938,200
Total Biogen Inc. shareholders’ equity 10,896,200 10,700,300 13,343,200 13,039,600 12,612,800
Total reported capital 18,169,300 18,126,500 19,298,000 18,976,100 18,551,000
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — 508,135 508,429
Add: Current operating lease liabilities (included in Accrued expenses and other)2 89,100 83,200 73,600 — —
Add: Long-term operating lease liabilities3 330,400 402,000 412,700 — —
Adjusted total debt 7,692,600 7,911,400 6,441,100 6,444,635 6,446,629
Adjustments to Equity
Less: Deferred tax assets (liabilities), net4 720,600 336,600 421,300 517,700 473,200
Add: Reserves for allowances 38,000 41,600 40,500 34,700 46,000
Add: Restructuring reserve — — — — 500
Add: Noncontrolling interests 63,500 (14,200) (4,100) (8,000) (14,700)
Adjusted total equity 10,277,100 10,391,100 12,958,300 12,548,600 12,171,400
After Adjustment
Adjusted total capital 17,969,700 18,302,500 19,399,400 18,993,235 18,618,029

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Current operating lease liabilities (included in Accrued expenses and other). See details »

3 Long-term operating lease liabilities. See details »

4 Deferred tax assets (liabilities), net. See details »


The capital structure exhibited relative stability between 2017 and 2019, followed by a significant shift in composition during the 2020 and 2021 fiscal years. A notable transition occurred in 2020, characterized by a simultaneous increase in total debt and a substantial reduction in shareholders' equity.

Debt Obligations and Trends
Total reported debt remained nearly constant from 2017 to 2019, hovering around 5.9 billion US$. A sharp increase is observed in 2020, where debt rose to 7.43 billion US$, representing a growth of approximately 25% within a single year. This peak was slightly moderated in 2021, with reported debt decreasing to 7.27 billion US$. Adjusted total debt consistently exceeds reported figures, maintaining a similar trajectory but reflecting higher liability levels, peaking at 7.91 billion US$ in 2020.
Equity Position and Volatility
Shareholders' equity showed a steady upward trend from 2017 to 2019, increasing from 12.61 billion US$ to 13.34 billion US$. However, a significant contraction occurred in 2020, with reported equity falling to 10.70 billion US$. While reported equity saw a marginal recovery to 10.90 billion US$ in 2021, adjusted total equity continued to decline, dropping from 10.39 billion US$ in 2020 to 10.28 billion US$ in 2021.
Capitalization Adjustments
A consistent divergence exists between reported and adjusted financial metrics. Adjusted total debt is systematically higher than reported debt, while adjusted total equity is systematically lower than reported equity. This indicates a conservative adjustment approach that recognizes additional liabilities and reduces the equity base for analysis purposes. Adjusted total capital followed a growth pattern until 2019, peaking at 19.40 billion US$, before declining to 17.97 billion US$ by 2021.
Overall Capital Structure Shift
The period from 2020 to 2021 marks a pivot in the capitalization profile. The increase in leverage, combined with the reduction in equity, indicates a shift toward a more debt-heavy capital structure. This is reflected in the adjusted total capital, which decreased by approximately 1.43 billion US$ between 2019 and 2021, driven primarily by the erosion of the equity base despite the increase in total debt.

AI Ask an analyst for more


Adjustments to Reported Income

Biogen Inc., adjusted net income attributable to Biogen Inc.

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Net income attributable to Biogen Inc. 1,556,100 4,000,600 5,888,500 4,430,700 2,539,100
Adjustments
Add: Deferred income tax expense (benefit)1 (426,800) 149,000 67,100 108,300 91,700
Add: Increase (decrease) in reserves for allowances (3,600) 1,100 5,800 (11,300) (5,200)
Add: Increase (decrease) in restructuring reserve — — — (500) (4,600)
Add: Other comprehensive income (loss), net of tax 192,900 (162,800) 104,800 76,100 1,500
Add: Comprehensive income (loss), net of tax, attributable to noncontrolling interest 172,100 60,900 (400) 42,900 131,000
After Adjustment
Adjusted net income 1,490,700 4,048,800 6,065,800 4,646,200 2,753,500

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Deferred income tax expense (benefit). See details »


An analysis of the reported and adjusted net income from 2017 to 2021 reveals a cyclical pattern characterized by an initial period of expansion followed by a significant contraction. Both metrics peaked in 2019 before entering a steep downward trajectory through 2021.

Net Income Trajectory
Net income attributable to the entity exhibited strong growth in the early part of the period, rising from 2,539,100 thousand US$ in 2017 to a peak of 5,888,500 thousand US$ in 2019. This growth was followed by a rapid decline, with figures falling to 4,000,600 thousand US$ in 2020 and reaching a period low of 1,556,100 thousand US$ by December 31, 2021.
Adjusted Net Income Performance
Adjusted net income mirrored the movement of reported net income, peaking in 2019 at 6,065,800 thousand US$. The subsequent contraction was severe, with the 2021 value of 1,490,700 thousand US$ representing a decrease of approximately 75% from the 2019 peak.
Analysis of Financial Adjustments
Between 2017 and 2020, adjusted net income was consistently higher than reported net income, indicating that non-GAAP adjustments primarily served to add back expenses or exclude one-time losses. The widest positive variance occurred in 2018, with a difference of 215,500 thousand US$. However, a reversal occurred in 2021, where reported net income exceeded adjusted net income by 65,400 thousand US$, signaling a shift in the composition of adjustments during the final year of the analyzed period.

AI Ask an analyst for more